Satsuma Pharmaceuticals Alpha and Beta Analysis
| STSADelisted Stock | USD 1.10 0.01 0.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Satsuma Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Satsuma Pharmaceuticals over a specified time horizon. Remember, high Satsuma Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Satsuma Pharmaceuticals' market risk premium analysis include:
Beta (0.64) | Alpha 0.58 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Satsuma |
Satsuma Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Satsuma Pharmaceuticals market risk premium is the additional return an investor will receive from holding Satsuma Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Satsuma Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Satsuma Pharmaceuticals' performance over market.| α | 0.58 | β | -0.64 |
Satsuma Pharmaceuticals Fundamentals Vs Peers
Comparing Satsuma Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Satsuma Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Satsuma Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Satsuma Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Satsuma Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Satsuma Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Satsuma Pharmaceuticals to competition |
| Fundamentals | Satsuma Pharmaceuticals | Peer Average |
| Return On Equity | -1.04 | -0.31 |
| Return On Asset | -0.5 | -0.14 |
| Current Valuation | (35.53 M) | 16.62 B |
| Shares Outstanding | 33.15 M | 571.82 M |
| Shares Owned By Insiders | 10.43 % | 10.09 % |
| Shares Owned By Institutions | 57.90 % | 39.21 % |
| Number Of Shares Shorted | 130.12 K | 4.71 M |
Satsuma Pharmaceuticals Opportunities
Satsuma Pharmaceuticals Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Satsuma Pharmaceuticals to Release Earnings on Friday | 03/17/2023 |
2 | Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal STSA | 04/17/2023 |
3 | SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana Kahn Swick Foti, LLC Investigates Adequacy of Price and Process in Proposed S... | 04/21/2023 |
4 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA | 04/25/2023 |
5 | STOCKHOLDER ALERT The MA Class Action Firm Continues the Investigation of the Merger - USX, OSH, TESS, - Benzinga | 04/28/2023 |
6 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates TESS, STSA, CHRA | 05/03/2023 |
7 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSA | 05/09/2023 |
8 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates MGTA, CHRA, STSA | 05/18/2023 |
About Satsuma Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Satsuma or other delisted stocks. Alpha measures the amount that position in Satsuma Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Satsuma Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Satsuma Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Satsuma Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Satsuma Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Satsuma Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Satsuma Pharmaceuticals' management manipulating its earnings.
| 8th of August 2023 Upcoming Quarterly Report | View | |
| 2nd of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Satsuma Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Satsuma Stock
If you are still planning to invest in Satsuma Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Satsuma Pharmaceuticals' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |